|
Active substance |
Canakinumab |
|
Holder |
Novartis |
|
Status |
Closed |
|
Indication |
Hereditary periodic fever |
|
Public documents |
|
|
Informed consent for children (8-<12years) Informed consent for children (>=12-18years) |
|
|
Last update |
23/07/2018 |
Ilaris®
Last updated on 13/09/2024